S&P 500   3,852.95 (+0.03%)
DOW   31,192.61 (+0.01%)
QQQ   325.88 (+0.65%)
AAPL   136.25 (+3.20%)
MSFT   226.00 (+0.74%)
FB   271.92 (+1.66%)
GOOGL   1,895.09 (+0.80%)
AMZN   3,321.79 (+1.79%)
TSLA   846.87 (-0.42%)
NVDA   545.00 (+1.94%)
BABA   259.18 (-2.38%)
CGC   33.85 (+0.65%)
GE   11.13 (-2.28%)
MU   83.49 (-0.01%)
AMD   90.45 (+1.92%)
NIO   57.63 (-0.14%)
T   28.89 (-0.24%)
F   11.72 (+7.92%)
ACB   11.15 (-3.38%)
BA   207.21 (-2.01%)
DIS   171.77 (-1.08%)
NFLX   573.50 (-2.19%)
GILD   66.91 (-1.59%)
S&P 500   3,852.95 (+0.03%)
DOW   31,192.61 (+0.01%)
QQQ   325.88 (+0.65%)
AAPL   136.25 (+3.20%)
MSFT   226.00 (+0.74%)
FB   271.92 (+1.66%)
GOOGL   1,895.09 (+0.80%)
AMZN   3,321.79 (+1.79%)
TSLA   846.87 (-0.42%)
NVDA   545.00 (+1.94%)
BABA   259.18 (-2.38%)
CGC   33.85 (+0.65%)
GE   11.13 (-2.28%)
MU   83.49 (-0.01%)
AMD   90.45 (+1.92%)
NIO   57.63 (-0.14%)
T   28.89 (-0.24%)
F   11.72 (+7.92%)
ACB   11.15 (-3.38%)
BA   207.21 (-2.01%)
DIS   171.77 (-1.08%)
NFLX   573.50 (-2.19%)
GILD   66.91 (-1.59%)
S&P 500   3,852.95 (+0.03%)
DOW   31,192.61 (+0.01%)
QQQ   325.88 (+0.65%)
AAPL   136.25 (+3.20%)
MSFT   226.00 (+0.74%)
FB   271.92 (+1.66%)
GOOGL   1,895.09 (+0.80%)
AMZN   3,321.79 (+1.79%)
TSLA   846.87 (-0.42%)
NVDA   545.00 (+1.94%)
BABA   259.18 (-2.38%)
CGC   33.85 (+0.65%)
GE   11.13 (-2.28%)
MU   83.49 (-0.01%)
AMD   90.45 (+1.92%)
NIO   57.63 (-0.14%)
T   28.89 (-0.24%)
F   11.72 (+7.92%)
ACB   11.15 (-3.38%)
BA   207.21 (-2.01%)
DIS   171.77 (-1.08%)
NFLX   573.50 (-2.19%)
GILD   66.91 (-1.59%)
S&P 500   3,852.95 (+0.03%)
DOW   31,192.61 (+0.01%)
QQQ   325.88 (+0.65%)
AAPL   136.25 (+3.20%)
MSFT   226.00 (+0.74%)
FB   271.92 (+1.66%)
GOOGL   1,895.09 (+0.80%)
AMZN   3,321.79 (+1.79%)
TSLA   846.87 (-0.42%)
NVDA   545.00 (+1.94%)
BABA   259.18 (-2.38%)
CGC   33.85 (+0.65%)
GE   11.13 (-2.28%)
MU   83.49 (-0.01%)
AMD   90.45 (+1.92%)
NIO   57.63 (-0.14%)
T   28.89 (-0.24%)
F   11.72 (+7.92%)
ACB   11.15 (-3.38%)
BA   207.21 (-2.01%)
DIS   171.77 (-1.08%)
NFLX   573.50 (-2.19%)
GILD   66.91 (-1.59%)
Log in
NYSE:NVRO

Nevro Stock Forecast, Price & News

$184.36
+7.14 (+4.03 %)
(As of 01/21/2021 01:20 PM ET)
Add
Compare
Today's Range
$177.56
Now: $184.36
$184.65
50-Day Range
$156.59
MA: $171.79
$184.34
52-Week Range
$65.05
Now: $184.36
$188.14
Volume7,098 shs
Average Volume650,241 shs
Market Capitalization$6.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. It also offers Senza II system and Senza Omnia system products for chronic pain. The company's solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. Nevro Corp. sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was founded in 2006 and is headquartered in Redwood City, California.
Nevro logo

MarketRank

Overall MarketRank

1.20 out of 5 stars

Medical Sector

808th out of 1,926 stocks

Surgical & Medical Instruments Industry

82nd out of 169 stocks

Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone650-251-0005
Employees853

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$390.26 million
Book Value$6.98 per share

Profitability

Net Income$-103,690,000.00

Miscellaneous

Market Cap$6.35 billion
Next Earnings Date2/24/2021 (Confirmed)
OptionableOptionable
$184.36
+7.14 (+4.03 %)
(As of 01/21/2021 01:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nevro (NYSE:NVRO) Frequently Asked Questions

How has Nevro's stock been impacted by Coronavirus (COVID-19)?

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has increased by 64.4% and is now trading at $180.55.
View which stocks have been most impacted by COVID-19
.

Is Nevro a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nevro stock.
View analyst ratings for Nevro
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Nevro?

Wall Street analysts have given Nevro a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nevro wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Thomas Greco's approval rating as Nevro's CEO?

538 employees have rated Nevro CEO Thomas Greco on Glassdoor.com. Thomas Greco has an approval rating of 63% among Nevro's employees. This puts Thomas Greco in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Nevro's next earnings date?

Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Nevro
.

How can I listen to Nevro's earnings call?

Nevro will be holding an earnings conference call on Wednesday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) posted its earnings results on Thursday, November, 5th. The medical equipment provider reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.59) by $0.30. The medical equipment provider had revenue of $108.46 million for the quarter, compared to the consensus estimate of $104 million. Nevro had a negative net margin of 24.46% and a negative return on equity of 30.25%. The firm's quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.58) EPS.
View Nevro's earnings history
.

What guidance has Nevro issued on next quarter's earnings?

Nevro updated its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $109.7-109.7 million, compared to the consensus revenue estimate of $106.54 million.

What price target have analysts set for NVRO?

13 brokerages have issued 1-year target prices for Nevro's stock. Their forecasts range from $100.00 to $215.00. On average, they anticipate Nevro's stock price to reach $178.92 in the next twelve months. This suggests that the stock has a possible downside of 0.9%.
View analysts' price targets for Nevro
or view Wall Street analyst' top-rated stocks.

Who are some of Nevro's key competitors?

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), The Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Who are Nevro's key executives?

Nevro's management team includes the following people:
  • Mr. D. Keith Grossman, Chairman, CEO & Pres (Age 61, Pay $1.6M)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 47, Pay $705.96k)
  • Mr. Michael Collier Carter, VP of Global Sales (Age 49, Pay $841.82k)
  • Mr. Andrew H. Galligan, Exec. Officer (Age 65, Pay $812.72k)
  • Ms. Niamh Louise Pellegrini, Chief Commercial Officer (Age 54, Pay $853.27k)
  • Mr. Roderick H. MacLeod, Chief Financial Officer
  • Mr. Patrick Schmitz, VP of Operations (Age 61)
  • Ms. Julie D. Dewey, VP of Investor Relations & Corp. Communications (Age 60)
  • Mr. Neeraj Teotia, VP of Marketing (Age 46)
  • Ms. Lori M. Ciano, Chief HR Officer (Age 58)

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by a variety of institutional and retail investors. Top institutional investors include Exchange Traded Concepts LLC (0.03%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro
.

Which major investors are buying Nevro stock?

NVRO stock was acquired by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle.
View insider buying and selling activity for Nevro
or or view top insider-buying stocks.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $180.55.

How big of a company is Nevro?

Nevro has a market capitalization of $6.22 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 853 workers across the globe.

What is Nevro's official website?

The official website for Nevro is www.nevro.com.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.